BindingDB logo
myBDB logout

7 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
25375908 9 Targeting aldose reductase for the treatment of diabetes complications and inflammatory diseases: new insights and future directions.EBI Universit£ degli Studi di Messina
22104435 54 Design, synthesis, and biological evaluation of novel (1-thioxo-1,2,3,4-tetrahydro-ß-carbolin-9-yl)acetic acids as selective inhibitors for AKR1B1.EBI University of Toyama
20936791 32 A diverse series of substituted benzenesulfonamides as aldose reductase inhibitors with antioxidant activity: design, synthesis, and in vitro activity.EBI Aristotle University of Thessaloniki
20304656 31 Chromene-3-carboxamide derivatives discovered from virtual screening as potent inhibitors of the tumour maker, AKR1B10.EBI Gifu Pharmaceutical University
16107153 10 Structure of aldehyde reductase holoenzyme in complex with the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity.EBI Monash University (Parkville Campus)
10882376 7 A potent aldose reductase inhibitor, (2S,4S)-6-fluoro-2', 5'-dioxospiro[chroman-4,4'-imidazolidine]-2-carboxamide (Fidarestat): its absolute configuration and interactions with the aldose reductase by X-ray crystallography.EBI Rational Drug Design Laboratories
15857120 81 Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications.BDB The Institute for Diabetes Discovery